文献速递骨质疏松与代谢性骨病

住院患者口服双膦酸盐的上消化道安全性

Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
PubMed 文献 · Osteoporos Int · 2020-07-14

这项单中心前瞻性队列研究纳入298例正在服用利塞膦酸或阿仑膦酸的住院成人患者,在基线和给药后1至5小时主动评估上消化道症状,发现32例(10.7%)出现胃和食管症状,作者认为不良反应发生率与社区试验报告相似,住院患者口服双膦酸盐不构成上消化道不良事件的额外风险。

要点

  • 住院患者口服双膦酸盐后上消化道症状发生率为10.7%(32/298)。
  • 胃灼烧感4.4%(n=13)、吞咽困难3%(n=9)、反流2.7%(n=8)、反酸2.3%(n=7)。
  • 作者认为住院患者口服双膦酸盐不增加上消化道不良事件风险。

核心结论

  • 口服双膦酸盐的不良反应发生率与社区试验报告相似。
  • 住院患者口服双膦酸盐不构成上消化道不良事件的额外风险。
  • 住院期间应优化治疗以改善骨质疏松的药物治疗管理。

研究设计与样本

  • 单中心前瞻性队列研究,纳入298例正在服用利塞膦酸或阿仑膦酸的住院成人患者。
  • 平均年龄64±15岁。
  • 在基线和口服双膦酸盐后1至5小时主动评估上消化道症状。

主要发现

  • 随访期间胃和食管症状影响32例患者(10.7%)。
  • 胃灼烧感报告于4.4%(n=13)的患者。
  • 吞咽困难报告于3%(n=9)的患者。
  • 反流报告于2.7%(n=8)的患者。
  • 反酸报告于2.3%(n=7)的患者。

临床怎么用

  • 作者认为住院期间应优化治疗以改善骨质疏松的药物治疗管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Oral bisphosphonates are effective medications for the prevention of fractures in people suffering from osteoporosis. They are associated with gastrointestinal adverse reactions the most severe being an esophageal ulcer. It is unclear if oral bisphosphonates have a similar gastrointestinal safety profile in the hospital setting as in the community setting because hospitalized patients are often bedridden which may hinder proper drug administration. INTRODUCTION: To evaluate the incidence of upper gastrointestinal symptoms in hospitalized patients taking oral bisphosphonate. METHODS: This single-center prospective cohort study included hospitalized adult patients actively taking risedronate or alendronate. Upper gastrointestinal symptoms were actively assessed at the baseline and 1 to 5 h following the administration of the oral bisphosphonate. RESULTS: A total of 298 patients were included in the study. The mean age was 64 ± 15 years. During the follow-up period, gastric and esophageal symptoms affected 32 patients (10.7%). Epigastric burning, dysphagia, and regurgitation were reported in 4.4% (n = 13), 3% (n = 9), 2.7 (n = 8), and 2.3% (n = 7) patients, respectively. Heartburn, retro-sternal pain, and odynophagia were observed in 1.7% (n = 5), 1.7% (n = 5), and 0.3% (n = 1) patients. CONCLUSION: The incidence of adverse reaction was similar to that reported in community trials. The administration of oral bisphosphonate in hospitalized patients does not represent an additional risk for upper gastrointestinal adverse events. Treatment should be optimized during the hospital stay to improve the pharmacological management of osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Nguyen PV, Bouin M, Ste-Marie LG, et al. Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. Osteoporos Int. 2020. PMID: 32666144. doi:10.1007/s00198-020-05498-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。